Search and Filter
Results per Page:
Fred Hutch study finds genetic driver of drug resistance in small cell lung cancer
Researchers use CRISPR-Cas9 gene-editing tool on tumor cells grown in mice to better model how tumors that initially respond to chemotherapy become resistant
Rare cancer researchers find promising target in fibrolamellar cancer
Fred Hutch’s TRACER initiative digs into aggressive liver cancer, hosts third rare cancer symposium
New methods reveal cancer mechanism in ancient genes
Fred Hutch researchers discover that overproduction of DNA packaging material predicts aggressive brain and breast tumors, which could lead to cheaper diagnostic tests and new drug therapies
Tricking cells into trashing cancer
Fred Hutch chemical biologist rapidly reduces lung tumors in mice with a tagging system that grabs cancer-causing proteins and hauls them out with the molecular trash
50 years of doing hard things
Founded in 1975 to honor a brother, Fred Hutch Cancer Center pursued bold science, pioneered a cure for blood diseases that changed medicine and became a world-class biomedical research and clinical care institution
Starting the year smarter
How patients, providers, researchers and others stay informed amid a deluge of data and information
Cracking the sparkle code
Fred Hutch cancer biologist wins V Foundation Scholar Award to explore role of protein sugaring in leukemia tumors that survive chemotherapy
Fred Hutch research shines at national oncology conference
Society for Immunotherapy of Cancer meeting features new discoveries on cancer-cell visualization, T-cell survival and new targets for solid tumors
Finding a new way to break the supply chain fueling advanced prostate cancer
Fred Hutch researcher wins a $1M grant for a London-Seattle collaboration to find new therapies for drug-resistant prostate cancer
Bottleneck breakthrough
Fred Hutch researchers discover why some HIV-1 variants are more transmissible than others, which could generate new approaches to stop the virus that causes AIDS at cell entry
Making the most of a small supply
Fred Hutch researchers receive $1.3 million grant from the U.S. Department of Defense to study the fundamental biology of five rare liver cancers that could lead to new treatments one day
Priming the pump for future funding
Fred Hutch postdoctoral researchers win NIH training fellowship for pancreatic cancer and kinetochore projects
A quarter century of lifesaving discoveries in prostate cancer
Pacific Northwest Prostate Cancer SPORE insights have transformed patient care and understanding of prostate cancer biology, supported drug discovery worldwide
Finding a rare bile duct cancer’s weaknesses
DOD and Cholangiocarcinoma Foundation awards will help Dr. Debraj Boila reveal genetics, drug targets of intrahepatic cholangiocarcinoma
More to brain tumors than meets the eye
Fred Hutch researchers find new way to classify tumors based on their underlying biology rather than how they look
$5.25M from the Kuni Foundation propels innovative adult oncology research
Grants will support research on tumor regression, immunotherapy access and better care for breast, liver and peritoneal malignancies
Fred Hutch and UW hematology/oncology fellows win ASCO Young Investigator Awards
Winners represent broad range of research
Mapping a pathway to hope
How Fred Hutch researchers revealed the biology behind a drug’s success in a rare liver cancer and paired it with another drug for a one-two punch
Tackling an aggressive form of pancreatic cancer
Dr. Stephanie Dobersch awarded American Cancer Society Fellowship to study genetics of basal pancreatic adenocarcinoma
Bridging the gap between cancer drug target and cancer drug
Fred Hutch RNA-translation expert Dr. Andrew Hsieh receives Harrington Scholar-Innovator Award to develop experimental compound into anti-cancer drug